{"nct_id":"NCT04700124","title":"Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-08","start_date":"2021-04-21","start_date_type":"ACTUAL","primary_completion_date":"2026-12-23","primary_completion_date_type":"ESTIMATED","completion_date":"2026-12-23","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["MRK"]}